Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07048457 · ClinicalTrials.gov registry record · Phase 2
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
A Phase 2 study of Locally Advanced Urothelial Carcinoma and Oligo-metastaic Urothelial Carcinoma, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07048457 is a Phase 2 study of Locally Advanced Urothelial Carcinoma and Oligo-metastaic Urothelial Carcinoma that is actively recruiting participants, run by Yale University. The registered enrollment target is 32 participants, below the 125-participant average among 14 other Locally Advanced Urothelial Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07048457, a Phase 2 study of Locally Advanced Urothelial Carcinoma and Oligo-metastaic Urothelial Carcinoma, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.
Conditions Studied
Interventions
- PROCEDURE Radical cystectomy
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07048457
The ClinicalTrials.gov registry entry for NCT07048457 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 14 other Locally Advanced Urothelial Carcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Locally Advanced Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radical cystectomy is the first listed.
NCT07048457 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07048457 about?
NCT07048457 is a clinical study titled "Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma". This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously rad...
What is the current status of trial NCT07048457?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-11-26. Estimated completion is 2028-11.
What conditions does trial NCT07048457 study?
This clinical trial studies the following conditions: Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma.
What interventions are being tested in trial NCT07048457?
The interventions under investigation include: Radical cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT07048457?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07048457 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ARID1A and/or KDM6A Mutation and CXCL13 Expression
ACTIVE NOT RECRUITING · Phase 2
-
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
RECRUITING · Phase 1
-
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RECRUITING · Phase 3
-
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Locally Advanced Urothelial Carcinoma
All registered trials for this condition
Oligo-metastaic Urothelial Carcinoma
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.